BridgeBio Pharma Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
556
- Stock Symbol
-
BBIO
- Investments
-
13
- Share Price
-
$25.08
- (As of Wednesday Closing)
BridgeBio Pharma General Information
Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Contact Information
Website
www.bridgebio.comCorporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
Corporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
BridgeBio Pharma Timeline
BridgeBio Pharma Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.08 | $24.80 | $21.62 - $44.32 | $4.72B | 188M | 1.85M | -$2.63 |
BridgeBio Pharma Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 5,961,736 | 8,228,623 | 2,270,865 | 3,262,073 |
| Revenue | 219,124 | 9,303 | 77,648 | 69,716 |
| EBITDA | (386,785) | (583,506) | (404,985) | (534,966) |
| Net Income | (453,819) | (643,202) | (481,183) | (562,539) |
| Total Assets | 794,375 | 546,380 | 623,036 | 1,012,792 |
| Total Debt | 1,729,281 | 1,739,838 | 1,723,564 | 1,726,171 |
BridgeBio Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BridgeBio Pharma Comparisons
Industry
Financing
Details
BridgeBio Pharma Competitors (86)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IVERIC bio | Formerly VC-backed | Parsippany, NJ | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
BridgeBio Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BridgeBio Pharma Patents
BridgeBio Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220040193-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Pending | 04-Aug-2020 | ||
| CA-3187759-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Pending | 04-Aug-2020 | ||
| EP-4192431-A1 | Formulations of phosphoinositide 3-kinase inhibitors | Pending | 04-Aug-2020 | ||
| CA-3127686-A1 | Topical phosphoinositide 3-kinase inhibitors | Pending | 06-Feb-2019 | ||
| AU-2020219065-A1 | Topical phosphoinositide 3-kinase inhibitors | Pending | 06-Feb-2019 | C07D495/04 |
BridgeBio Pharma Executive Team (23)
| Name | Title | Board Seat |
|---|---|---|
| Neil Kumar Ph.D | Co-Founder, Chief Executive Officer & Board Member | |
| Christine Siu | Chief Operating Officer in-residence | |
| Thomas Trimarchi | Chief Operating Officer, Operations & President | |
| Jonathan Fox Ph.D | Chief Medical Officer & President | |
| Brian Stephenson | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
BridgeBio Pharma Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ali Satvat | Kohlberg Kravis Roberts | Director | |
| Andrew Lo Ph.D | Self | Board Member | |
| Brenton Saunders JD | Self | Board Member | |
| Charles Homcy MD | Self | Chairman & Board Member | |
| Douglas Dachille | American International Group | Board Member |
BridgeBio Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BridgeBio Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BridgeBio Pharma Investments & Acquisitions (13)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| GondolaBio | 16-Aug-2024 | Drug Discovery | |||
| Eidos Therapeutics | 26-Jan-2021 | Drug Discovery | |||
| Contour Therapeutics | 07-Dec-2020 | Drug Discovery | |||
| Retinagenix Holdings | 01-Feb-2019 | Drug Discovery | |||
| Alexion (cyclic pyranopterin monophosphate) | 11-Jun-2018 | Corporate Asset Purchase | Buildings and Property |
BridgeBio Pharma Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| QED Therapeutics | Biotechnology | Brisbane, CA | 2018 |
| BridgeBio Pharma (Rare Pediatric Disease Priority Review Voucher) | Buildings and Property | Palo Alto, CA |
BridgeBio Pharma ESG
Risk Overview
Risk Rating
Updated September, 29, 2023
35.7 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Pharmaceuticals
Subindustry
of 446
Rank
Percentile
BridgeBio Pharma Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Retinagenix Holdings | 01-Feb-2019 | Completed |
|
BridgeBio Pharma FAQs
-
When was BridgeBio Pharma founded?
BridgeBio Pharma was founded in 2015.
-
Who is the founder of BridgeBio Pharma?
Neil Kumar Ph.D, Seth Merrin, and Frank McCormick Ph.D are the founders of BridgeBio Pharma.
-
Who is the CEO of BridgeBio Pharma?
Neil Kumar Ph.D, Christine Siu, Eric David MD, and Eli Wallace Ph.D are the CEOs of BridgeBio Pharma.
-
Where is BridgeBio Pharma headquartered?
BridgeBio Pharma is headquartered in Palo Alto, CA.
-
What is the size of BridgeBio Pharma?
BridgeBio Pharma has 556 total employees.
-
What industry is BridgeBio Pharma in?
BridgeBio Pharma’s primary industry is Biotechnology.
-
Is BridgeBio Pharma a private or public company?
BridgeBio Pharma is a Public company.
-
What is BridgeBio Pharma’s stock symbol?
The ticker symbol for BridgeBio Pharma is BBIO.
-
What is the current stock price of BridgeBio Pharma?
As of 02-Oct-2024 the stock price of BridgeBio Pharma is $25.08.
-
What is the current market cap of BridgeBio Pharma?
The current market capitalization of BridgeBio Pharma is $4.72B.
-
What is BridgeBio Pharma’s current revenue?
The trailing twelve month revenue for BridgeBio Pharma is $219M.
-
Who are BridgeBio Pharma’s competitors?
IVERIC bio, Regenxbio, NGM Biopharmaceuticals, Renova Therapeutics, and Poseida Therapeutics are some of the 86 competitors of BridgeBio Pharma.
-
What is BridgeBio Pharma’s annual earnings per share (EPS)?
BridgeBio Pharma’s EPS for 12 months was -$2.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
